[{"id":"e7bc5bbe-b288-4c17-bc36-59b57b203c7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990479","created_at":"2021-08-04T13:53:05.021Z","updated_at":"2024-07-02T16:35:53.458Z","phase":"Phase 1b","brief_title":"Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma","source_id_and_acronym":"NCT04990479","lead_sponsor":"Nouscom SRL","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NOUS-PEV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2023-03-13"}]